Document is current
Any future updates will be listed below
-
Authors
Otsuki, Noriko
Kato, Tamaki
Yokomura, Mamoru
Urano, Mari
Matsuo, Mari
Kobayashi, Emiko
Haginoya, Kazuhiro
Awano, Hiroyuki
Takeshima, Yasuhiro
Saito, Toshio
Saito, Kayoko https://orcid.org/0000-0003-2632-0873
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (JPMH23FC1008)
Practical Research Project for Rare/Intractable Diseases of the Japan Agency for Medical Research and Development, AMED (20ek0109472h0001, 21ek0109472h0002, 22ek0109472h0003)
Global All Bio-Genome Equity Fund donation program
- License Information
-
More Information
Article History
Received: 19 March 2024
Accepted: 8 February 2025
First Online: 28 February 2025
Declarations
:
: Subject recruitment was conducted at TWMU Hospital under Institutional Review Board-approved protocols, specifically No. 4786 and No. 5639. All procedures adhered to the ethical principles of the Declaration of Helsinki.
: Written informed consent was meticulously acquired from the participants and/or their legal guardians in accordance with institutional guidelines.
: KS is a site principal investigator for Biogen, Novartis Gene Therapies, Inc., and Chugai/Roche clinical trials; has served on advisory boards for Novartis Gene Therapies, Inc. /Novartis, Biogen, and Chugai/Roche; and has received speaker’s fees from Biogen, Novartis, and Chugai/ Roche. The other authors declare that they have no competing interests.
